慢性肾脏病患者血管钙化相关生物学标志物
|
摘要
血管钙化是慢性肾脏病患者心血管死亡的主要原因,是患者死亡率强有力的预测因子。随着慢性肾脏病的进展,血管钙化发生率不断增加。因此需要找到预测血管钙化的生物标志物,用来预测未来心血管事件发生率和致死率,进行相应干预,改善患者预后。现已有不少关于慢性肾脏病患者血管钙化生物标志物的相关研究,文章就这些生物标志物进行了简要的综述。
Vascular calcification( VC) is associated with an increased cardiovascular morbimortality in chronic kidney disease( CKD). The prevalence of VC increases steadily through the stages of chronic kidney disease. Well-designed clinical trials are urgently needed to test the potential value of these biomarkers as a guide for interventions targeting VC now. This review gives a brief overview of the circulating biomarkers of vascular calcification in CKD patients.
Vascular calcification( VC) is associated with an increased cardiovascular morbimortality in chronic kidney disease( CKD). The prevalence of VC increases steadily through the stages of chronic kidney disease. Well-designed clinical trials are urgently needed to test the potential value of these biomarkers as a guide for interventions targeting VC now. This review gives a brief overview of the circulating biomarkers of vascular calcification in CKD patients.
引文
[1]Rong S,Qiu X,Jin X,et al. Risk factors for heart valve calcification in chronic kidney disease[J]. Medicine(Baltimore),2018,97(5):e9804.
[2]Rennenberg RJ,Kessels AG,Schurgers LJ,et al. Vascular calcifications as a marker of increased cardiovascular risk:a meta-analysis[J]. Vasc Health Risk Manag,2009,5:185-197.
[3]Mizuiri S,Nishizawa Y,Yamashita K,et al. Coronary artery calcification score and common iliac artery calcification score in nondialysis CKD patients[J]. Nephrology(Carlton),2018,23(9):837-845.
[4]Bundy JD,Chen J,Yang W,et al. Risk factors for progression of coronary artery calcification in patients with chronic kidney disease:the CRIC study[J]. Atherosclerosis,2018,271:53-60.
[5]Adeney KL,Siscovick DS,Ix JH,et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD[J].J Am Soc Nephrol,2009,20(2):381-387.
[6]Zhao FL,Zhang YZ,Tai GX,et al. Serum parathyroid hormone as a potential novel biomarker of coronary heart disease[J]. Genet Test Mol Biomarkers,2014,18(10):670-674.
[7]张小红,陈财铭,万建新.非透析慢性肾脏病患者骨量异常与血管钙化的危险因素[J].中华肾脏病杂志,2017,33(2):100-105.
[8]Agarwal G,Nanda G,Kapoor A,et al. Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy:results of a prospective case control study[J]. Surgery,2013,154(6):1394-1403.
[9]Buizert PJ,van Schoor NM,Simsek S,et al. PTH:a new target in arteriosclerosis[J]. Clin Endocrinol Metab, 2013, 98(10):E1583-E1590.
[10]Tamei N,Ogawa T,Ishida H,et al. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis[J]. J Atheroscler Thromb,2011,18:217-223.
[11]Desjardins L,Liabeuf S,Renard C,et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages[J]. Osteoporos Int,2011,7:2017-2025.
[12]Gan L,Zhou Q. Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban,2017,42(9):1058-1065.
[13]Isakova T,Xie H,Yang W,et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease[J]. JAMA,2011,305(23):2432-2439.
[14]Abdel-Azeez HA,Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease:association with echocardiographic characteristics of atherosclerosis[J]. J Clin Lab Anal, 2010, 24:201-206.
[15]Bozic M,Méndez-Barbero N,Gutiérrez-Mu1oz C,et al. Combination of biomarkers of vascular calcification and s TWEAK to predict cardiovascular events in chronic kidney disease[J]. Atherosclerosis,2018,270:13-20.
[16]Barreto DV,Lenglet A,Liabeuf S,et al. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease[J]. Nephron Clin Pract,2011,117(4):c363-372.
[17]Lin F,Wang G,Koh JL,et al. In vivo and noninvasive three-dimensional patellar tracking induced by individual heads of quadriceps[J]. Med Sci Sports Exerc,2004,36(1):93-101.
[18] Elsaeed AM,Ibrahiem AH,Ali AA. Matrix metalloproteinase 2and osteoprotegrin as new markers of increased atherosclerotic risk in egyptian patients with chronic kidney disease[J]. Egypt J Immunol,2017,24(1):153-164.
[19]Karsli Ceppio4lu S,Yurdun T,Canbakan M. Assessment of matrix Gla protein,Klotho gene polymorphisms,and oxidative stress in chronic kidney disease[J]. Ren Fail,2011,33(9):866-874.
[20]Cranenburg EC,Brandenburg VM,Vermeer C,et al. Uncarboxylated matrix Gla protein(uc MGP)is associated with coronary artery calcification in haemodialysis patients[J]. Thromb Haemost,2009,101:359-366.
[21]Cranenburg EC,Vermeer C,Koos R,et al. The circulating inactive form of matrix Gla protein(uc MGP)as a biomarker for cardiovascular calcification[J]. J Vasc Res,2008,45:427-436.
[22]Azpiazu D,Gonzalo S,González-Parra E,et al. Role of pyrophosphate in vascular calcification in chronic kidney disease[J]. Nefrologia,2018,38(3):250-257.
[23]O'Neill WC,Sigrist MK,Mc Intyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease[J]. Nephrol Dial Transplant,2010,25:187-191.
[24]Lomashvili KA,Garg P,Narisawa S,et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis:potential mechanism for uremic vascular calcification[J]. Kidney Int,2008,73(9):1024-1030.
[25]Mehrotra R. Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease[J]. Kidney Int,2007,72(2):137-140.
[26] Schoppet M,Rauner M,Benner J,et al. Serum fetuin-A levels and abdominal aortic calcification in healthy men-the STRAMBO study[J]. Bone,2015,79:196-202.
[27]Kanbay M,Nicoleta M,Selcoki Y,et al. Fibroblast growth factor23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease[J]. Clin J Am Soc Nephrol,2010,5(10):1780-1786.
[28]Roos M,von Eynatten M,Heemann U,et al. Serum fetuin-A,cardiovascular risk factors,and six-year follow-up outcome in patients with coronary heart disease[J]. Am J Cardiol,2010,105(12):1666-1672.
[29] Sakaguchi Y,Hamano T,Nakano C,et al. Association between density of coronary artery calcification and serum magnesium levels among patients with chronic kidney disease[J]. PLoS One,2016,11(9):e0163673.
[30] Sakaguchi Y,Hamano T,Isaka Y. Effects of magnesium on the phosphate toxicity in chronic kidney disease:time for intervention studies[J]. Nutrients,2017,9(2). doi:10.3390/nu9020112.
[31]Sakaguchi Y,Fujii N,Shoji T,et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis[J]. Kidney Int,2014,85(1):174-181.
[32]Massy ZA,Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease:focus on vascular calcification,atherosclerosis and survival[J]. Clin Kidney J,2012,5(Suppl 1):i52-i61.
[33]Li Y,Chen C,Liu HL,et al. Vitamin D,parathyroid hormone,and heart failure in a Chinese elderly population[J]. Endocr Pract,2015,21(1):30-40.
[34]Lau WL,Leaf EM,Hu MC,et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet[J].Kidney Int,2012,82(12):1261-1270.
[35]Zheng Z,Shi H,Jia J,et al. Vitamin D supplementation and mortality risk in chronic kidney disease:a meta-analysis of 20 observational studies[J]. BMC Nephrol,2013,14:199.
[36]Muslimovic A,Tulumovic D,Hasanspahic S,et al. Serum cystatin C-marker of inflammation and cardiovascular morbidity in chronic kidney disease stages 1-4[J]. Mater Sociomed,2015,27(2):75-78.
[37] Ruiz-Salas A,Cortés-Rodríguez M,Alegre-Bayo N,et al. Relationship between cystatin C and coronary artery calcification in patients with intermediate cardiovascular risk[J]. Med Clin(Barc),2014,143(12):535-538.
[38]侯凡凡,王骏.重视高同型半胱氨酸血症在慢性肾脏病患者心血管并发症中的作用[J].肾脏病与透析肾移植杂志,2012,21(2):148-149.
[39]Haarhaus M,Brandenburg V,Kalantar-Zadeh K,et al. Alkaline phosphatase:a novel treatment target for cardiovascular disease in CKD[J]. Nat Rev Nephrol,2017,13(7):429-442.
[40]齐永芬.关注血管钙化的基础和临床研究[J].中国动脉硬化杂志,2015,23(5):433-436.
[2]Rennenberg RJ,Kessels AG,Schurgers LJ,et al. Vascular calcifications as a marker of increased cardiovascular risk:a meta-analysis[J]. Vasc Health Risk Manag,2009,5:185-197.
[3]Mizuiri S,Nishizawa Y,Yamashita K,et al. Coronary artery calcification score and common iliac artery calcification score in nondialysis CKD patients[J]. Nephrology(Carlton),2018,23(9):837-845.
[4]Bundy JD,Chen J,Yang W,et al. Risk factors for progression of coronary artery calcification in patients with chronic kidney disease:the CRIC study[J]. Atherosclerosis,2018,271:53-60.
[5]Adeney KL,Siscovick DS,Ix JH,et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD[J].J Am Soc Nephrol,2009,20(2):381-387.
[6]Zhao FL,Zhang YZ,Tai GX,et al. Serum parathyroid hormone as a potential novel biomarker of coronary heart disease[J]. Genet Test Mol Biomarkers,2014,18(10):670-674.
[7]张小红,陈财铭,万建新.非透析慢性肾脏病患者骨量异常与血管钙化的危险因素[J].中华肾脏病杂志,2017,33(2):100-105.
[8]Agarwal G,Nanda G,Kapoor A,et al. Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy:results of a prospective case control study[J]. Surgery,2013,154(6):1394-1403.
[9]Buizert PJ,van Schoor NM,Simsek S,et al. PTH:a new target in arteriosclerosis[J]. Clin Endocrinol Metab, 2013, 98(10):E1583-E1590.
[10]Tamei N,Ogawa T,Ishida H,et al. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis[J]. J Atheroscler Thromb,2011,18:217-223.
[11]Desjardins L,Liabeuf S,Renard C,et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages[J]. Osteoporos Int,2011,7:2017-2025.
[12]Gan L,Zhou Q. Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban,2017,42(9):1058-1065.
[13]Isakova T,Xie H,Yang W,et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease[J]. JAMA,2011,305(23):2432-2439.
[14]Abdel-Azeez HA,Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease:association with echocardiographic characteristics of atherosclerosis[J]. J Clin Lab Anal, 2010, 24:201-206.
[15]Bozic M,Méndez-Barbero N,Gutiérrez-Mu1oz C,et al. Combination of biomarkers of vascular calcification and s TWEAK to predict cardiovascular events in chronic kidney disease[J]. Atherosclerosis,2018,270:13-20.
[16]Barreto DV,Lenglet A,Liabeuf S,et al. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease[J]. Nephron Clin Pract,2011,117(4):c363-372.
[17]Lin F,Wang G,Koh JL,et al. In vivo and noninvasive three-dimensional patellar tracking induced by individual heads of quadriceps[J]. Med Sci Sports Exerc,2004,36(1):93-101.
[18] Elsaeed AM,Ibrahiem AH,Ali AA. Matrix metalloproteinase 2and osteoprotegrin as new markers of increased atherosclerotic risk in egyptian patients with chronic kidney disease[J]. Egypt J Immunol,2017,24(1):153-164.
[19]Karsli Ceppio4lu S,Yurdun T,Canbakan M. Assessment of matrix Gla protein,Klotho gene polymorphisms,and oxidative stress in chronic kidney disease[J]. Ren Fail,2011,33(9):866-874.
[20]Cranenburg EC,Brandenburg VM,Vermeer C,et al. Uncarboxylated matrix Gla protein(uc MGP)is associated with coronary artery calcification in haemodialysis patients[J]. Thromb Haemost,2009,101:359-366.
[21]Cranenburg EC,Vermeer C,Koos R,et al. The circulating inactive form of matrix Gla protein(uc MGP)as a biomarker for cardiovascular calcification[J]. J Vasc Res,2008,45:427-436.
[22]Azpiazu D,Gonzalo S,González-Parra E,et al. Role of pyrophosphate in vascular calcification in chronic kidney disease[J]. Nefrologia,2018,38(3):250-257.
[23]O'Neill WC,Sigrist MK,Mc Intyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease[J]. Nephrol Dial Transplant,2010,25:187-191.
[24]Lomashvili KA,Garg P,Narisawa S,et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis:potential mechanism for uremic vascular calcification[J]. Kidney Int,2008,73(9):1024-1030.
[25]Mehrotra R. Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease[J]. Kidney Int,2007,72(2):137-140.
[26] Schoppet M,Rauner M,Benner J,et al. Serum fetuin-A levels and abdominal aortic calcification in healthy men-the STRAMBO study[J]. Bone,2015,79:196-202.
[27]Kanbay M,Nicoleta M,Selcoki Y,et al. Fibroblast growth factor23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease[J]. Clin J Am Soc Nephrol,2010,5(10):1780-1786.
[28]Roos M,von Eynatten M,Heemann U,et al. Serum fetuin-A,cardiovascular risk factors,and six-year follow-up outcome in patients with coronary heart disease[J]. Am J Cardiol,2010,105(12):1666-1672.
[29] Sakaguchi Y,Hamano T,Nakano C,et al. Association between density of coronary artery calcification and serum magnesium levels among patients with chronic kidney disease[J]. PLoS One,2016,11(9):e0163673.
[30] Sakaguchi Y,Hamano T,Isaka Y. Effects of magnesium on the phosphate toxicity in chronic kidney disease:time for intervention studies[J]. Nutrients,2017,9(2). doi:10.3390/nu9020112.
[31]Sakaguchi Y,Fujii N,Shoji T,et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis[J]. Kidney Int,2014,85(1):174-181.
[32]Massy ZA,Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease:focus on vascular calcification,atherosclerosis and survival[J]. Clin Kidney J,2012,5(Suppl 1):i52-i61.
[33]Li Y,Chen C,Liu HL,et al. Vitamin D,parathyroid hormone,and heart failure in a Chinese elderly population[J]. Endocr Pract,2015,21(1):30-40.
[34]Lau WL,Leaf EM,Hu MC,et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet[J].Kidney Int,2012,82(12):1261-1270.
[35]Zheng Z,Shi H,Jia J,et al. Vitamin D supplementation and mortality risk in chronic kidney disease:a meta-analysis of 20 observational studies[J]. BMC Nephrol,2013,14:199.
[36]Muslimovic A,Tulumovic D,Hasanspahic S,et al. Serum cystatin C-marker of inflammation and cardiovascular morbidity in chronic kidney disease stages 1-4[J]. Mater Sociomed,2015,27(2):75-78.
[37] Ruiz-Salas A,Cortés-Rodríguez M,Alegre-Bayo N,et al. Relationship between cystatin C and coronary artery calcification in patients with intermediate cardiovascular risk[J]. Med Clin(Barc),2014,143(12):535-538.
[38]侯凡凡,王骏.重视高同型半胱氨酸血症在慢性肾脏病患者心血管并发症中的作用[J].肾脏病与透析肾移植杂志,2012,21(2):148-149.
[39]Haarhaus M,Brandenburg V,Kalantar-Zadeh K,et al. Alkaline phosphatase:a novel treatment target for cardiovascular disease in CKD[J]. Nat Rev Nephrol,2017,13(7):429-442.
[40]齐永芬.关注血管钙化的基础和临床研究[J].中国动脉硬化杂志,2015,23(5):433-436.